Search

Your search keyword '"Tufman, Amanda"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Tufman, Amanda" Remove constraint Author: "Tufman, Amanda" Database Unpaywall Remove constraint Database: Unpaywall
145 results on '"Tufman, Amanda"'

Search Results

1. Corrigendum to “First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations” [Eur J Cancer 199 (2024) 113556]

2. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade

5. Herausgeber

6. Pneumologie

7. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

9. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

10. Early mortality in German patients with lung cancer: risk factors associated with 30-and 60-day mortality

14. Pneumologie

15. Autorinnen und Autoren

16. Evaluation of solitary pulmonary nodules

17. Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment

19. Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study

21. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients

24. Chinese never smokers with adenocarcinoma of the lung are younger and have fewer lymph node metastases than smokers

26. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis

27. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

28. COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies

29. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions

30. Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study

32. Treatment patterns and prognosis in inoperable stage III NSCLC after concurrent chemoradiotherapy with or without immune checkpoint inhibition: Historical overview.

33. Treatment patterns and outcomes in resectable early stage NSCLC: Interim analysis of a global real-world study.

34. Pattern of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy with/without immune checkpoint inhibition.

35. Propensity-matched analysis of concurrent/sequential versus sequential immune checkpoint inhibition in inoperable stage III NSCLC patients treated with chemoradiotherapy.

38. Autorinnen und Autoren

39. Pneumologie

40. Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire

42. Lymphocytes and sinus histiocytosis in tumor and matched lymph nodes as predictors of survival in non-small-cell lung cancer

43. Changes in Behavior After Vaccination and Opinions Toward Mask Wearing: Thoracic Oncology Patient–Reported Experiences During the COVID-19 Pandemic

46. Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations

48. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition

50. Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)

Catalog

Books, media, physical & digital resources